Nilofer Azad

The Johns Hopkins University, School of Medicine

Nilofer Azad; Arvind Dasari; John Arcaroli; Gretchen E Taylor; Daniel A Laheru; Michael A Carducci; Martine McManus; Kevin Quackenbush; John J Wright; Manuel Hidalgo; et al.

Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.

Jung-min Lee; John L Hays; Anne M Noonan; Jennifer Squires; Lori Minasian; Christina Annunziata; Bradford J Wood; Minshu Yu; Katherine R Calvo; Nicole Houston; et al.

Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.

M Zulfiquer Hossain; Megan A Healey; Calvin Lee; Weijie Poh; Sashidhar R Yerram; Kalpesh Patel; Nilofer S Azad; James G Herman; Scott E Kern

DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cells.

Joseph M Herman; Amol K Narang; Kent A Griffith; Mark M Zalupski; Jennifer B Reese; Susan L Gearhart; Nolifer S Azad; June Chan; Leah Olsen; Jonathan E Efron; et al.

The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer.

Elizabeth Sugar; Adam J Pascoe; Nilofer Azad

Reporting of preclinical tumor-graft cancer therapeutic studies.

Kalpesh Patel; Sashidhar R Yerram; Nilofer A Azad; Scott E Kern

A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.

Jessica A Smith; Aaron T Wild; Aatur Singhi; Siva P Raman; Haoming Qiu; Rachit Kumar; Amy Hacker-Prietz; Ralph H Hruban; Ihab R Kamel; Jonathan Efron; et al.

Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal Cancer.

Salma K Jabbour; Shyamal Patel; Joseph M Herman; Aaron Wild; Suneel N Nagda; Taghrid Altoos; Ahmet Tunceroglu; Nilofer Azad; Susan Gearheart; Rebecca A Moss; et al.

Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits.

William E Jones; Charles R Thomas; Joseph M Herman; May Abdel-Wahab; Nilofer Azad; William Blackstock; Prajnan Das; Karyn A Goodman; Theodore S Hong; Salma K Jabbour; et al.

ACR appropriateness criteria®  resectable rectal cancer.

J-M Lee; G A Sarosy; C M Annunziata; N Azad; L Minasian; H Kotz; J Squires; N Houston; E C Kohn

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.

Diane K Reyes; Josephina A Vossen; Ihab R Kamel; Nilofer S Azad; Tamara A Wahlin; Michael S Torbenson; Michael A Choti; Jean-Francois H Geschwind

Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.

Nilofer Azad; Alyssa Perroy; Erin Gardner; Chiyo K Imamura; Cynthia Graves; Gisele A Sarosy; Lori Minasian; Herbert Kotz; Miranda Raggio; William D Figg; et al.

A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.

Nilofer S Azad; Jeanny B Aragon-Ching; William L Dahut; Martin Gutierrez; William D Figg; Lokesh Jain; Seth M Steinberg; Maria L Turner; Elise C Kohn; Heidi H Kong

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Nilofer S Azad; Edwin M Posadas; Virginia E Kwitkowski; Seth M Steinberg; Lokesh Jain; Christina M Annunziata; Lori Minasian; Gisele Sarosy; Herbert L Kotz; Ahalya Premkumar; et al.

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Nilofer S Azad; Christina M Annunziata; Seth M Steinberg; Lori Minasian; Ahalya Premkumar; Catherine Chow; Herbert L Kotz; Elise C Kohn

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.

C M Annunziata; N Azad; A S Dhamoon; G Whiteley; E C Kohn

Ovarian cancer in the proteomics era.

Amit S Dhamoon; Elise C Kohn; Nilofer S Azad

The ongoing evolution of proteomics in malignancy.

Elise C Kohn; Nilofer Azad; Christina Annunziata; Amit S Dhamoon; Gordon Whiteley

Proteomics as a tool for biomarker discovery.

Heidi H Kong; Edward W Cowen; Nilofer S Azad; William Dahut; Martin Gutierrez; Maria L Turner

Keratoacanthomas associated with sorafenib therapy.

Nilofer S Azad; Nabila Rasool; Christina M Annunziata; Lori Minasian; Gordon Whiteley; Elise C Kohn

Proteomics in clinical trials and practice: present uses and future promise.

J K Bhama; N S Azad; W E Fisher

Primary anorectal lymphoma presenting as a perianal abscess in an HIV-positive male.